Merck Forecast, price target & analysts
Merck Target price 2025 - Analyst rating & recommendation
Merck Classifications & Recommendation:
Merck Price Target
| Target Price | €174.19 |
| Price | €118.95 |
| Potential | 46.44% |
| Number of Estimates | 16 |
| 16 Analysts have issued a price target Merck 2026 . The average Merck target price is €174.19. This is 46.44% higher than the current stock price. The highest price target is €206.00 73.18% , the lowest is €107.00 10.05% . | |
| A rating was issued by 18 analysts: 15 Analysts recommend Merck to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 46.44% . Most analysts recommend the Merck stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
15 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €22.0b . This is 3.80% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €22.4b 5.74% , the lowest is €21.2b 0.21% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €21.2b | 0.78% |
|---|---|---|
| 2025 | €22.0b | 3.80% |
| 2026 | €22.8b | 4.05% |
| 2027 | €23.7b | 3.86% |
| 2028 | €24.9b | 4.90% |
| 2029 | €26.1b | 4.67% |
15 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.3b . This is 5.13% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.6b 0.84% , the lowest is €6.0b 10.30% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €6.2b | 5.89% |
|---|---|---|
| 2025 | €6.3b | 2.44% |
| 2026 | €6.8b | 7.05% |
| 2027 | €7.1b | 4.77% |
| 2028 | €7.4b | 4.41% |
| 2029 | €7.9b | 6.64% |
EBITDA Margin
| 2024 | 29.15% | 5.07% |
|---|---|---|
| 2025 | 28.77% | 1.32% |
| 2026 | 29.60% | 2.88% |
| 2027 | 29.86% | 0.88% |
| 2028 | 29.73% | 0.44% |
| 2029 | 30.29% | 1.88% |
12 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €3.3b . This is 20.21% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €4.0b 44.76% , the lowest is €2.8b 0.94% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €2.8b | 1.69% |
|---|---|---|
| 2025 | €3.3b | 20.21% |
| 2026 | €3.7b | 11.78% |
| 2027 | €4.0b | 7.88% |
| 2028 | €4.1b | 3.01% |
| 2029 | €4.4b | 5.84% |
Net Margin
| 2024 | 13.13% | 2.45% |
|---|---|---|
| 2025 | 15.21% | 15.82% |
| 2026 | 16.34% | 7.43% |
| 2027 | 16.97% | 3.86% |
| 2028 | 16.67% | 1.77% |
| 2029 | 16.85% | 1.08% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
12 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €7.68 . This is 20.19% higher than earnings per share in the financial year 2024. The highest EPS forecast is €9.25 44.76% , the lowest is €6.45 0.94% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €6.39 | 1.69% |
|---|---|---|
| 2025 | €7.68 | 20.19% |
| 2026 | €8.59 | 11.85% |
| 2027 | €9.26 | 7.80% |
| 2028 | €9.54 | 3.02% |
| 2029 | €10.10 | 5.87% |
P/E ratio
| Current | 18.62 | 21.24% |
|---|---|---|
| 2025 | 15.49 | 16.81% |
| 2026 | 13.85 | 10.59% |
| 2027 | 12.84 | 7.29% |
| 2028 | 12.47 | 2.88% |
| 2029 | 11.78 | 5.53% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.71 and an P/S ratio of 2.36 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.82 | 20.56% |
|---|---|---|
| 2025 | 2.71 | 3.79% |
| 2026 | 2.61 | 3.89% |
| 2027 | 2.51 | 3.72% |
| 2028 | 2.39 | 4.67% |
| 2029 | 2.29 | 4.46% |
P/S ratio
| Current | 2.44 | 23.16% |
|---|---|---|
| 2025 | 2.36 | 3.66% |
| 2026 | 2.26 | 3.89% |
| 2027 | 2.18 | 3.72% |
| 2028 | 2.08 | 4.67% |
| 2029 | 1.99 | 4.46% |
Current Merck Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Apr 06 2025 |
| DZ BANK |
Buy
➜
Buy
|
Unchanged | Apr 01 2025 |
| DAY BY DAY |
Sell
➜
Sell
|
Unchanged | Mar 30 2025 |
| HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
| EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Mar 16 2025 |
| ODDO BHF |
Buy
➜
Buy
|
Unchanged | Mar 10 2025 |
| JEFFERIES |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Apr 06 2025 |
|
Unchanged
DZ BANK:
Buy
➜
Buy
|
Apr 01 2025 |
|
Unchanged
DAY BY DAY:
Sell
➜
Sell
|
Mar 30 2025 |
|
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
|
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Mar 16 2025 |
|
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Mar 10 2025 |
|
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Mar 05 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
